Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

Esther Rossi, Maurizio Martini, Celestino Pio Lombardi, Alfredo Pontecorvi, Luigi Maria Larocca, Sara Capodimonti, Tonia Cenci, Patrizia Straccia, Basilio Angrisani, Paola Lanza, Guido Fadda

Risultato della ricerca: Contributo in rivistaArticolo in rivista

38 Citazioni (Scopus)

Abstract

It has been generally demonstrated that the valine-to-glutamic acid substitution at position 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is an effective diagnostic/prognostic marker mainly for papillary thyroid carcinoma (PTC). The detection of this mutation typically has been achieved using DNA-based techniques. The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. The authors investigated molecular and immunocytohistochemical BRAF analyses in a prospective series of samples from patients with PTC.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaCancer cytopathology
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • BRAF mutation
  • VE1 immunomarker
  • immunochemistry
  • liquid-based cytology
  • thyroid papillary carcinoma

Fingerprint Entra nei temi di ricerca di 'Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience'. Insieme formano una fingerprint unica.

Cita questo